Clinical Trial Update: Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure [Phase 2]

View source ↗

Summary

Phase 2 trial comparing pemetrexed alone versus pemetrexed plus cisplatin in EGFR-mutant non-small cell lung cancer after failure of first-line EGFR-TKI therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN